Role of the newer alpha, -adrenergic-receptor antagonistsin the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms
- 1 November 2004
- journal article
- review article
- Published by Elsevier in Clinical Therapeutics
- Vol. 26 (11) , 1701-1713
- https://doi.org/10.1016/j.clinthera.2004.11.006
Abstract
No abstract availableKeywords
This publication has 73 references indexed in Scilit:
- Quality of life and α-blocker therapy: an important consideration for both the patient and the physicianUrology, 2002
- Goals for benign prostatic hyperplasia therapy.Urology, 2002
- Terazosin, doxazosin, and prazosin: current clinical experienceUrology, 2001
- The natural history of benign prostatic hyperplasia: what have we learned in the last decade?Urology, 2000
- Impact of drug therapy on benign prostatic hyperplasia-specific quality of lifeUrology, 1999
- Drug Treatment—Antihypertensive Drugs—The Present Role of Beta Blockers and Alpha BlockersClinical and Experimental Hypertension, 1999
- Controversies in the management of lower urinary tract symptoms: an overviewBritish Journal of Urology, 1998
- High prevalence of benign prostatic hypertrophy in the communityThe Lancet, 1991
- Sexual dysfunction in hypertensive men. A critical review of the literature.Hypertension, 1988
- The Development of Human Benign Prostatic Hyperplasia with AgeJournal of Urology, 1984